title: Is antibacterial therapy against Campylobacter pylori useful in the treatment of indigestion and chronic peptic ulceration?
abstract: Campylobacter pylori is a spiral Gram-negative rod that was first identified in human gastric mucosa in 1906. Since 1983, interest in the organism has been renewed; it was first cultured, and has since been found to be very strongly associated with the histologic presence of antral gastritis. Further, it has been suggested that this organism may play a role in peptic ulceration. C. pylori is sensitive to many different antibiotics as well as to bismuth. However, recrudescence of infection after treatment is exceedingly common. Nick Talley and JoAnn Ormand advise that further investigation is needed to delineate if C. pylori is truly a clinically important pathogen, before antimicrobial therapy can be recommended; only thereafter will it be appropriate to determine what represents optimal therapy.
authors.forename: N J
authors.initials: NJ
authors.lastname: Talley
authors.forename: J E
authors.initials: JE
authors.lastname: Ormand
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002167:Campylobacter / Q000187:drug effects*; D004066:Digestive System Diseases / Q000188:drug therapy*; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents